AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36189733 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ACB
Number of subjects: 50
Study 36189733 — intervention group
Group type: COMPARATOR
Intervention: Postoperative ACB
Number of subjects: 50
Study 33782832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Number of subjects: 66
Study 33782832 — intervention group
Group type: COMPARATOR
Intervention: SNAC alone
Number of subjects: 66
Study 32788532 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG)
Number of subjects: 46
Study 32788532 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 46
Study 32788532 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) and Control Group (CG)
Number of subjects: 46
Study 35622206 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning fed (B)
Number of subjects: 41
Study 35622206 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening fasted (C)
Number of subjects: 41
Study 35622206 — intervention group
Group type: COMPARATOR
Intervention: Morning fasted (A)
Number of subjects: 41
Study 32571602 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational handout for self-management of stiffness
Number of subjects: 120
Study 32571602 — intervention group
Group type: COMPARATOR
Intervention: One-on-one hand therapy in addition to the handout
Number of subjects: 120
Study 32771678 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (gamma frequency, 40 Hz) - group 1: two 10-min stimulations per day for ten days
Number of subjects: 6
Study 32771678 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (gamma frequency, 40 Hz) - group 2: one 20-min stimulation per day for ten days
Number of subjects: 6
Study 34403836 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC <1-month group
Number of subjects: 431
Study 34403836 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC 1-2-month group
Number of subjects: 431
Study 34403836 — intervention group
Group type: EXPERIMENTAL
Intervention: DISC 3-5-month group
Number of subjects: 431
Study 34403836 — intervention group
Group type: COMPARATOR
Intervention: Continuous group
Number of subjects: 431
Study 34233376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention according to the Progressively Lowered Stress Threshold (PLST) model
Number of subjects: 29
Study 36242777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Effort Discounting paradigm (Cog‐ED) under gain framing
Number of subjects: 310
Study 36242777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Effort Discounting paradigm (Cog‐ED) under loss framing
Number of subjects: 310
Study 36242777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Effort Discounting paradigm (Cog‐ED)
Number of subjects: 310
Study 35587847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-hypo-fractionated radiotherapy (UHF, 42.7 Gy in 7 fractions, 3 days per week for 2.5 weeks)
Number of subjects: 879
Study 35587847 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF, 78.0 Gy in 39 fractions, 5 days per week for 8 weeks)
Number of subjects: 879
Study 34533489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole (7.5 mg/kg for neonates and infants; 10-20 mg/kg for children 3 months to 17 years)
Number of subjects: 2
Study 34533489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole (10-20 mg/kg with a maximum of 500 mg per dose every 8 hours for up to 14 days)
Number of subjects: 2
Study 35033562 — intervention group
Group type: EXPERIMENTAL
Intervention: NICU2HOME app
Number of subjects: 298
Study 35033562 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 298
Study 32681219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) fortnightly over 10 weeks
Number of subjects: 30
Study 32681219 — intervention group
Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (MA) weekly over 10 weeks
Number of subjects: 30
Study 35672873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided curettage combined with hysteroscopic electro-resection after injection of pituitrin
Number of subjects: 60
Study 35672873 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic electro-resection after methotrexate chemotherapy
Number of subjects: 60
Study 34282125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-exposure psychotherapy with hydrocortisone augmentation
Number of subjects: 0
Study 34282125 — intervention group
Group type: COMPARATOR
Intervention: Prolonged-exposure psychotherapy without hydrocortisone augmentation
Number of subjects: 0
Study 33579256 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage revision procedure
Number of subjects: 96
Study 33579256 — intervention group
Group type: COMPARATOR
Intervention: Two-stage revision procedure
Number of subjects: 96
Study 34529050 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS >1000 AU
Number of subjects: 1769
Study 34529050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-attenuation plaque burden
Number of subjects: 1769
Study 34529050 — intervention group
Group type: COMPARATOR
Intervention: Zero CACS
Number of subjects: 1769
Study 34529050 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-calcified and low-attenuation plaque burden
Number of subjects: 1769
Study 33248750 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling to the fibularis longus
Number of subjects: 50
Study 33248750 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 50
Study 33653149 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching treatment for amblyopia
Number of subjects: 10
Study 33653149 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular reading performance of treated amblyopes
Number of subjects: 10
Study 33653149 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye from treated amblyopes
Number of subjects: 10
Study 32250167 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP/enzastaurin
Number of subjects: 0
Study 32250167 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 0
Study 35802818 — intervention group
Group type: EXPERIMENTAL
Intervention: Myths and facts education
Number of subjects: 152
Study 35802818 — intervention group
Group type: COMPARATOR
Intervention: Facts only education
Number of subjects: 152
Study 33395173 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario-based simulation training
Number of subjects: 122
Study 33395173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulation training)
Number of subjects: 122
Study 612949064 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (once daily with breast milk)
Number of subjects: 108
Study 612949064 — intervention group
Group type: COMPARATOR
Intervention: Control (breast milk without probiotics)
Number of subjects: 108
Study 34024551 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Fat Tolerance Test (AFTT)
Number of subjects: 20
Study 34024551 — intervention group
Group type: COMPARATOR
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 20
Study 32207067 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 4622
Study 34473373 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific instruction for female first responders (10 min oral delivery by a staff physician)
Number of subjects: 364
Study 34473373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gender-specific instruction)
Number of subjects: 364
Study 34531573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully automated closed-loop glucose control
Number of subjects: 0
Study 34531573 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 0
Study 32857060 — intervention group
Group type: EXPERIMENTAL
Intervention: SurgCare app
Number of subjects: 80
Study 32857060 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (manual recording)
Number of subjects: 80
Study 34406364 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (640 mg at week 0, 320 mg every 2 weeks)
Number of subjects: 90
Study 34406364 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 90
Study 34406364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 34406364 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (160 mg at week 0, 80 mg at week 2, 40 mg every week for weeks 4-10)
Number of subjects: 90
Study 34406364 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 90
Study 33433609 — intervention group
Group type: EXPERIMENTAL
Intervention: Committers (362/1,313)
Number of subjects: 1313
Study 33433609 — intervention group
Group type: COMPARATOR
Intervention: Disengagers (576/1,313)
Number of subjects: 1313
Study 33433609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryers (375/1,313)
Number of subjects: 1313
Study 36444905 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Number of subjects: 0
Study 36444905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35645073 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp-based oral health promotion programme
Number of subjects: 140
Study 32957331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting and lying Liuzijue
Number of subjects: 64
Study 32957331 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment and nursing
Number of subjects: 64
Study 36170291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive virtual reality model (group AN)
Number of subjects: 16
Study 36170291 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reactive virtual reality model (group NA)
Number of subjects: 16
Study 33620480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led educational intervention plus standard care
Number of subjects: 20
Study 33620480 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-ICD implantation care
Number of subjects: 20
Study 32628266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban, 15 mg/d
Number of subjects: 7213
Study 32628266 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 100 mg/d
Number of subjects: 7213
Study 32628266 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 7213
Study 32628266 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of infarct
Number of subjects: 7213
Study 34854342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (Mindfulness‐Acceptance‐Commitment programme for 7 weeks)
Number of subjects: 45
Study 34854342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45
Study 32901316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal rituximab (25 mg every 6 months)
Number of subjects: 14
Study 32901316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal rituximab
Number of subjects: 14
Study 35758724 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarke score
Number of subjects: 43
Study 35758724 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) measures of hypoglycemia exposure
Number of subjects: 43
Study 35758724 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite threshold of IAH-Clarke ≥4 with ROC curve-derived thresholds for CGM measures of hypoglycemia exposure
Number of subjects: 43
Study 35758724 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrics for predicting defective glucose counterregulation by the EGP response
Number of subjects: 43
Study 32764462 — intervention group
Group type: EXPERIMENTAL
Intervention: high lycopene + low lutein (HLyLLu)
Number of subjects: 28
Study 32764462 — intervention group
Group type: EXPERIMENTAL
Intervention: high lycopene + high lutein (HLyHLu)
Number of subjects: 28
Study 32764462 — intervention group
Group type: EXPERIMENTAL
Intervention: low lycopene + high lutein (LLyHLu)
Number of subjects: 28
Study 32764462 — intervention group
Group type: EXPERIMENTAL
Intervention: low lycopene + low lutein (LLyLLu)
Number of subjects: 28
Study 33582402 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified risk factors regarding child protection referrals of unborn babies
Number of subjects: 338
Study 33582402 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use, alcohol use, age, antenatal care attendance, mental wellbeing, domestic violence, childhood experiences
Number of subjects: 338
Study 33582402 — intervention group
Group type: COMPARATOR
Intervention: Midwives and social workers
Number of subjects: 338
Study 32186107 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus methotrexate (MTX) + leflunomide (LEF)
Number of subjects: 60
Study 32186107 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus MTX + LEF
Number of subjects: 60
Study 32186107 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) + leflunomide (LEF) (Control group)
Number of subjects: 60
Study 35774017 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter‐based thrombus removal (CBTR)
Number of subjects: 48
Study 34344360 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating long chain acylcarnitines (LCAC) levels in heart failure patients with diabetes mellitus (DM)
Number of subjects: 664
Study 34344360 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating long chain acylcarnitines (LCAC) levels in heart failure patients without diabetes mellitus (DM)
Number of subjects: 664
Study 34344360 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in LCAC levels after exercise in heart failure patients with diabetes mellitus (DM)
Number of subjects: 664
Study 34344360 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in LCAC levels after exercise in heart failure patients without diabetes mellitus (DM)
Number of subjects: 664
Study 34344360 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to primary clinical outcome in heart failure patients with diabetes mellitus (DM)
Number of subjects: 664
Study 34344360 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to primary clinical outcome in heart failure patients without diabetes mellitus (DM)
Number of subjects: 664
Study 34344360 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual metabolites (C16, C16:1, C18, C18:1) in heart failure patients
Number of subjects: 664
Study 34344360 — intervention group
Group type: COMPARATOR
Intervention: Control group of patients without heart failure from the CATHGEN study
Number of subjects: 664
Study 35473736 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment
Number of subjects: 98
Study 35473736 — intervention group
Group type: COMPARATOR
Intervention: Adenotonsillectomy (AT)
Number of subjects: 98
Study 34977534 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Exercise Therapy Application (DETA)
Number of subjects: 60
Study 34977534 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physical Therapy (PT)
Number of subjects: 60
Study 32213768 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2FPO3/CaCO3 fluoride toothpaste (1,378 µg F/g total soluble fluoride)
Number of subjects: 10
Study 32213768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged fluoride toothpaste (1,160 µg F/g total soluble fluoride)
Number of subjects: 10
Study 32213768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged fluoride toothpaste (900 µg F/g total soluble fluoride)
Number of subjects: 10
Study 32213768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged fluoride toothpaste (597 µg F/g total soluble fluoride)
Number of subjects: 10
Study 32213768 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride placebo toothpaste
Number of subjects: 10
Study 33043775 — intervention group
Group type: EXPERIMENTAL
Intervention: AC discordance
Number of subjects: 236
Study 33043775 — intervention group
Group type: EXPERIMENTAL
Intervention: sEFW discordance
Number of subjects: 236
Study 33302871 — intervention group
Group type: EXPERIMENTAL
Intervention: TeamCare (TC) - blended collaborative care for 12 months
Number of subjects: 440
Study 33302871 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 440
Study 34240669 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (15 weeks, 3 times per week)
Number of subjects: 65
Study 34240669 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 65
Study 33722403 — intervention group
Group type: COMPARATOR
Intervention: Enalapril + Losartan (Group A)
Number of subjects: 31
Study 33722403 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Losartan + Amiloride (Group B)
Number of subjects: 31
Study 34058419 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 2331
Study 34058419 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 2331
Study 34058419 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (steroid and placebo)
Number of subjects: 2331
Study 34058419 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior pregnancy with neonatal respiratory morbidity
Number of subjects: 2331
Study 34688506 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote SafERteens
Number of subjects: 122
Study 34688506 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person SafERteens
Number of subjects: 122
Study 34688506 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 122
Study 33145642 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab 9 mg
Number of subjects: 30
Study 33145642 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab 18 mg
Number of subjects: 30
Study 33145642 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab 27 mg
Number of subjects: 30
Study 33145642 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab (all doses)
Number of subjects: 30
Study 33145642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32394438 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy and fasting-mimicking diet
Number of subjects: 20
Study 32394438 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy only
Number of subjects: 20
Study 33662243 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy (AAT) with an emotional support canine in the child's lap
Number of subjects: 47
Study 33662243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no animal assisted therapy)
Number of subjects: 47
Study 33168129 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment (HT) during the RCT study phase
Number of subjects: 0
Study 33168129 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment (HT) under routine care conditions
Number of subjects: 0
Study 33168129 — intervention group
Group type: COMPARATOR
Intervention: Hospital ward treatment
Number of subjects: 0
Study 36191758 — intervention group
Group type: EXPERIMENTAL
Intervention: CordellaTM PAP Sensor
Number of subjects: 0
Study 36191758 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control arm
Number of subjects: 0
Study 34520941 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisory neglect
Number of subjects: 11208
Study 34520941 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative review of 150 cases
Number of subjects: 11208
Study 34520941 — intervention group
Group type: EXPERIMENTAL
Intervention: Child exposure to domestic violence
Number of subjects: 11208
Study 34520941 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's substance-related problems
Number of subjects: 11208
Study 34520941 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of factors
Number of subjects: 11208
Study 32213899 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate (5 g)
Number of subjects: 10
Study 32213899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34698342 — intervention group
Group type: EXPERIMENTAL
Intervention: Free distribution of oral rehydration salts (ORS) via home deliveries prior to diarrhoea onset
Number of subjects: 4
Study 34698342 — intervention group
Group type: EXPERIMENTAL
Intervention: Free distribution via vouchers
Number of subjects: 4
Study 34698342 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door sales model
Number of subjects: 4
Study 34698342 — intervention group
Group type: COMPARATOR
Intervention: Control arm (normal activities by CHWs)
Number of subjects: 4
Study 34130906 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 64
Study 34130906 — intervention group
Group type: COMPARATOR
Intervention: Friendly Visits
Number of subjects: 64
Study 32764872 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium histolyticum (CCH) 0.58 mg
Number of subjects: 11
Study 32764872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 36122258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg over 30 minutes, continuous infusion for 24 hours)
Number of subjects: 90
Study 36122258 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (same volume as nefopam solution, administered in the same manner)
Number of subjects: 90
Study 32237208 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided learning for managing stress (CALMS) integrated with family therapy for 12 weeks
Number of subjects: 11
Study 33040101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (20 weekly sessions)
Number of subjects: 30
Study 33040101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 36070117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarsofrontalis sling surgery using silicon rod
Number of subjects: 44
Study 36070117 — intervention group
Group type: COMPARATOR
Intervention: Supramaximal levator resection
Number of subjects: 44
Study 34425501 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical cannabis/cannabis-based medicine (MC/CBM)
Number of subjects: 0
Study 32915972 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day decitabine combined with ibrutinib (560 mg; sequentially given, starting the day after the last dose of decitabine) (n = 72)
Number of subjects: 144
Study 32915972 — intervention group
Group type: COMPARATOR
Intervention: 10-day decitabine (n = 72)
Number of subjects: 144
Study 32915972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (decitabine plus ibrutinib and decitabine)
Number of subjects: 144